Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke

Abstract

Transcranial magnetic stimulation (TMS) is an accessible, non-invasive technique to study cortical function in vivo. TMS studies have provided important pathophysiological insights across a range of neurodegenerative disorders and enhanced our understanding of brain reorganisation after stroke. In neurodegenerative disease, TMS has provided novel insights into the function of cortical output cells and the related intracortical interneuronal networks. Characterisation of cortical hyperexcitability in amyotrophic lateral sclerosis and altered motor cortical function in frontotemporal dementia, demonstration of cholinergic deficits in Alzheimer's disease and Parkinson's disease are key examples where TMS has led to advances in understanding of disease pathophysiology and potential mechanisms of propagation, with the potential for diagnostic applications. In stroke, TMS methodology has facilitated the understanding of cortical reorganisation that underlie functional recovery. These insights are critical to the development of effective and targeted rehabilitation strategies in stroke. The present review will provide an overview of cortical function measures obtained using TMS and how such measures may provide insight into brain function. Through an improved understanding of cortical function across a range of neurodegenerative disorders, and identification of changes in neural structure and function associated with stroke that underlie clinical recovery, more targeted therapeutic approaches may now be developed in an evolving era of precision medicine.

Metformin Protects against Oxidative Stress Injury Induced by Ischemia/Reperfusion via Regulation of the lncRNA-H19/miR-148a-3p/Rock2 Axis

“…The classic drug design approach is aimed at developing a drug that targets a single protein or signaling pathway for the treatment of disease [37]. However, many neurological diseases such as stroke and neurodegenerative diseases may require multiple treatments due to their complexity [38]. In this study, we found that metformin exerts neuroprotective effects on I/R injury induced by OGD/R or MCAO/R.…”

Intensive upper limb neurorehabilitation in chronic stroke: outcomes from the Queen Square programme

“…The second point to make is that we found no strong clinical indicators, among our measured explanatory variables, of which patients were most likely to change, including sensory loss in the hand, fatigue25 and depression (tables 4 and 5). It might be that neurophysiological (presence or absence of motor evoked potentials),26 neuroimaging (assessment of corticospinal tract, whole brain damage or brain function)27–30 or cognitive (sustained attention, memory, motivation)31 32 measures are required for accurate stratification based on likely response, and this can certainly be tested in future.…”

Cortical and Striatal Circuits in Huntington’s Disease

“…The cortex of HD mutation carriers shows progressive regional thinning in a topographically predictable manner already up to 15 years before the onset of motor symptoms (Rosas et al, 2005(Rosas et al, , 2008Nopoulos et al, 2010). On a functional level, one of the earliest events in HD is increased cortical excitability and impaired GABA-mediated cortical inhibition, as shown by transcranial magnetic stimulation studies already in the presymptomatic phase of the disease (Nardone et al, 2007;Schippling et al, 2009;Philpott et al, 2016;Agarwal et al, 2019).…”